Encephalopathy Connectomic Collapse Atlas (ECCA-TX) | Toxic Encephalopathy Biomarker Panel

SCF-ECCA-TX-BIO-0001

Toxic Encephalopathy Biomarker Panel

FDA-Aligned Endpoint Validation Framework for Precision Acupuncture Planning

Encephalopathy Connectomic Collapse Atlas (ECCA-TX)

I. PURPOSE

The SCF Toxic Encephalopathy Biomarker Panel is designed to:

Establish diagnostic confirmation
Quantify connectomic collapse severity
Predict progression risk
Stratify acupuncture neurocircuit selection
Monitor therapeutic response
Generate personalized neuromodulation maps
Support FDA-aligned translational endpoint development

II. SCF TOXIC ENCEPHALOPATHY BIOMARKER DOMAINS

Domain	Function
Exposure Burden	Quantifies toxicant load
Neuroaxonal Injury	Measures neuronal damage
Neuroglial Activation	Measures astrocyte/microglial response
BBB Integrity	Measures neurovascular injury
Connectomic Function	Measures network synchronization
Neuroimmune Status	Measures inflammatory activity
Mitochondrial Function	Measures bioenergetic collapse
Autonomic Function	Measures neuro-autonomic stability
Cognitive Function	Measures cortical performance
Recovery Prediction	Forecasts therapeutic response

III. EXPOSURE BURDEN PANEL

Tier 1 Diagnostic Layer

Biomarker	Assay	Normal Baseline	Mild Risk	Moderate Risk	Severe Risk
Blood Lead	ICP-MS	<5 µg/dL	5–10	10–25	>25
Blood Mercury	ICP-MS	<5 µg/L	5–10	10–20	>20
Blood Arsenic	ICP-MS	<10 µg/L	10–20	20–50	>50
Manganese	ICP-MS	4–15 µg/L	15–20	20–30	>30
VOC Metabolites	LC-MS/MS	Reference range	>1 SD	>2 SD	>3 SD
Organic Solvent Metabolites	GC-MS	ND	Detectable	Elevated	High

FDA-Compatible Assays

ICP-MS
LC-MS/MS
GC-MS
CLIA-certified toxicology platforms

IV. NEUROAXONAL INJURY PANEL

Tier 2 Connectomic Injury Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
NfL	Simoa	<10 pg/mL	10–20	20–50	>50
Total Tau	Simoa	<2 pg/mL	2–4	4–8	>8
UCH-L1	ELISA	<100 pg/mL	100–200	200–400	>400
NSE	CLIA	<12 ng/mL	12–18	18–25	>25

Endpoint

Neuroaxonal Injury Index (NAII)

V. GLIAL ACTIVATION PANEL

Tier 3 Neuroimmune Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
GFAP	Simoa	<120 pg/mL	120–250	250–500	>500
S100B	Immunoassay	<0.1 ng/mL	0.1–0.2	0.2–0.5	>0.5
YKL-40	ELISA	<60 ng/mL	60–100	100–150	>150
sTREM2	ELISA	Reference	Elevated	High	Very High

Endpoint

Glial Activation Severity Score (GASS)

VI. BBB INTEGRITY PANEL

Tier 4 Neurovascular Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
S100B	Immunoassay	<0.1	0.1–0.2	0.2–0.5	>0.5
Albumin Quotient	CSF/Serum	<6.5	6.5–8	8–12	>12
MMP-9	ELISA	<150 ng/mL	150–250	250–400	>400
VEGF	ELISA	Normal	Elevated	High	Very High

Endpoint

BBB Permeability Index (BBPI)

VII. NEUROIMMUNE PANEL

Tier 5 Inflammatory Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
IL-6	Multiplex	<2 pg/mL	2–10	10–50	>50
TNF-α	Multiplex	<5 pg/mL	5–15	15–30	>30
IL-1β	Multiplex	<1 pg/mL	1–5	5–15	>15
CRP	hsCRP	<1 mg/L	1–3	3–10	>10

Endpoint

Neuroimmune Collapse Score (NICS)

VIII. MITOCHONDRIAL COLLAPSE PANEL

Tier 6 Bioenergetic Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
Lactate	Clinical Chemistry	0.5–2.0 mmol/L	2–3	3–5	>5
Pyruvate	LC-MS	Normal	Elevated	High	Very High
Lactate/Pyruvate Ratio	LC-MS	<20	20–30	30–40	>40
ATP Production Rate	Seahorse	Normal	↓10%	↓25%	↓50%

Endpoint

Bioenergetic Failure Index (BFI)

IX. CONNECTOMIC FUNCTION PANEL

Tier 7 Network Synchronization Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
EEG Delta Power	qEEG	Normal	+20%	+50%	+100%
EEG Theta Excess	qEEG	Normal	Mild	Moderate	Severe
Alpha Connectivity	qEEG	Normal	↓10%	↓25%	↓50%
Global Functional Connectivity	rs-fMRI	Normal	↓10%	↓25%	↓50%
DTI Fractional Anisotropy	MRI-DTI	Normal	↓5%	↓10%	↓20%

Endpoint

Connectomic Collapse Index (CCI)

X. AUTONOMIC FUNCTION PANEL

Tier 8 Neuro-Autonomic Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
HRV SDNN	ECG	>100 ms	80–100	50–80	<50
RMSSD	ECG	>30 ms	20–30	10–20	<10
LF/HF Ratio	HRV	1–2	2–3	3–5	>5
Orthostatic HR Increase	Tilt Table	<20 bpm	20–30	30–40	>40

Endpoint

Autonomic Collapse Index (ACI)

XI. COGNITIVE ENDPOINT PANEL

Tier 9 Functional Layer

Endpoint	Normal	Mild	Moderate	Severe
MoCA	≥26	22–25	16–21	<16
Digit Symbol Substitution	>90	75–90	50–75	<50
Trail Making Test B	<75 sec	75–120	120–180	>180
Processing Speed	Normal	Mild decline	Moderate decline	Severe decline

Endpoint

Cognitive Connectomic Performance Score (CCPS)

XII. SCF ACUPUNCTURE RESPONSE FORECAST PANEL

Personalized Therapeutic Planning Layer

Biomarker Pattern	Predicted Circuit Dysfunction	Primary Acupuncture Network
Elevated IL-6 + TNFα	Neuroimmune hyperactivation	ST36 + LI11 + LI4
Elevated GFAP + S100B	BBB-glial injury	GV20 + ST36 + PC6
High NfL + Tau	Neuroaxonal injury	GV20 + Sishencong + GB20
High Lactate/Pyruvate	Mitochondrial collapse	KI3 + SP6 + ST36
HRV suppression	Dysautonomia	PC6 + HT7 + CV17
Reduced rs-fMRI connectivity	Connectomic collapse	GV20 + GV24 + Sishencong

XIII. SCF PRECISION FORECASTING MODEL

Low-Risk Recovery

Criteria:

NfL <20
GFAP <250
HRV preserved
MoCA >24

Predicted Response:

Rapid neuromodulation responsiveness

Intermediate Risk

Criteria:

NfL 20–50
GFAP 250–500
Moderate EEG slowing
MoCA 18–24

Predicted Response:

Partial response requiring prolonged treatment

High-Risk Progression

Criteria:

NfL >50
GFAP >500
Severe connectivity loss
HRV collapse
MoCA <18

Predicted Response:

Low likelihood of neuromodulation-only benefit; requires intensive multidisciplinary intervention

XIV. COMPOSITE SCF TOXIC ENCEPHALOPATHY SCORE (SCF-TXES)

Weighted domains:

Exposure Burden = 15%
Neuroaxonal Injury = 15%
Glial Activation = 15%
BBB Integrity = 10%
Neuroimmune Activity = 10%
Mitochondrial Function = 10%
Connectomics = 15%
Autonomics = 5%
Cognition = 5%

Interpretation

Score	Classification
<20	Stable
20–40	Mild Connectomic Disruption
40–60	Moderate Collapse
60–80	Severe Collapse
>80	Critical Connectomic Failure

NEXT PANEL IN SEQUENCE

SCF-ECCA-HEP-BIO-0002

Hepatic Encephalopathy Biomarker Panel

(Liver–Gut–Brain Axis Connectomic Collapse Validation System)

MASTER REGISTRY INDEX

SCF-ECCA-TX-BIO-0001 — Toxic Encephalopathy Biomarker Panel
SCF-ECCA-TX-ACU-0001 — Toxic Encephalopathy Acupoint Neuro-Circuit Mapping Atlas
SCF-ECCA-0001 — Encephalopathy Connectomic Collapse Atlas
SCF-PATH-PROT-0001 — SCF Pathophysiology Protocol
SCF-ACU-NEURO-ATLAS-0001 — SCF Neural Mapping Schema
SCF-BIOMARKER-ENDPOINTS-0001 — SCF Biomarker Endpoint Validation Framework